Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Strontium ranelate].

Hideki Masaki1, Takami Miki

  • 1Geriatric Medicine, Postgraduate School of Medicine, Osaka City University Medical School.

Clinical Calcium
|January 7, 2006
PubMed
Summary

Strontium ranelate is an oral osteoporosis drug with dual bone action. While clinically proven and approved globally, its Japanese clinical trial is ongoing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Xenophagocytosis blockade enhances interspecies chimerism.

Cell·2026
Same author

Xenophagocytosis blockade enhances interspecies chimerism.

bioRxiv : the preprint server for biology·2025
Same author

Derivation of resident macrophages and construction of tumor microenvironment in Flk-1-knockout chimeric mice produced via blastocyst complementation.

Scientific reports·2025
Same author

Allogeneic, Xenogeneic, and Exogenic Hearts for Transplantation.

Methodist DeBakey cardiovascular journal·2025
Same author

Inhibition of PRC2 enables self-renewal of blastoid-competent naive pluripotent stem cells from chimpanzee.

Cell stem cell·2025
Same author

Intercellular mRNA transfer alters the human pluripotent stem cell state.

Proceedings of the National Academy of Sciences of the United States of America·2025

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Context:

  • Osteoporosis is a prevalent bone disease characterized by low bone mass and microarchitectural deterioration.
  • Current osteoporosis treatments primarily focus on inhibiting bone resorption.
  • There is a need for therapies that also promote bone formation.

Purpose:

  • To evaluate the efficacy and safety of strontium ranelate as a novel therapeutic agent for osteoporosis.
  • To highlight the dual mechanism of action of strontium ranelate in managing bone loss.

Summary:

  • Strontium ranelate is an orally active medication demonstrating a dual effect on bone metabolism.
  • It effectively reduces bone resorption and simultaneously enhances bone formation.
  • Clinical evidence supports its value in treating osteoporosis.

Impact:

  • Strontium ranelate offers a promising therapeutic option for osteoporosis management.
  • Its unique dual action addresses both bone loss and bone building.
  • Ongoing clinical trials, including those in Japan, will further define its global therapeutic role.

Related Experiment Videos